JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF
Summary
- Eligibility
- for people ages 40-80 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Jeffrey Golden, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jeffrey Golden, MD
Professor, Medicine. Authored (or co-authored) 200 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Nitto Denko Corporation
- ID
- NCT03538301
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated